Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreasEuropean Journal of Cancer, 2014
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trialThe Lancet Oncology, 2014
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactionsNature, 2013
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 InactivationCancer Research, 2012
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerBritish Journal of Cancer, 2012
- CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and BleomycinMolecular Cancer Therapeutics, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic CancerJournal of Clinical Oncology, 2009
- Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpointMolecular Cancer Therapeutics, 2007